India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect children from the coronavirus. It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion. Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of AstraZeneca's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.

India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect children from the coronavirus. It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion. Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of AstraZeneca's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.